Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Uncovering the roles of dihydropyrimidine dehydrogenase in fatty-acid induced steatosis using human cellular models

18 Aug 2022

Abstract excerpt

Pyrimidine catabolism is implicated in hepatic steatosis. Dihydropyrimidine dehydrogenase (DPYD) is an enzyme responsible for uracil and thymine catabolism, and DPYD human genetic variability affects clinically observed toxicity following 5-Fluorouracil administration. In an in vitro model of fatty acid-induced steatosis, the pharmacologic inhibition of DPYD resulted in protection from lipid accumulation....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Liver Disease Diagnosis and Treatment
Share to Metabolism, Diabetes, and Cancer
Share to Pancreatic function and diabetes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35982095
DOI: 10.1038/s41598-022-17860-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Uncovering the roles of dihydropyrimidine dehydrogenase in fatty-acid induced steatosis using human cellular modelsPMID 35982095Read ↗

Identifying Dihydropyrimidine Dehydrogenase as a Novel Regulator of Hepatic SteatosisSemantic proximity Read ↗

Identifying Dihydropyrimidine Dehydrogenase as a Novel Regulator of Hepatic SteatosisSemantic proximity Read ↗

Deoxyguanosine Kinase Deficiency Couples Purine Metabolism to Innate Immune Activation and Lipid Accumulation in HepatocytesSemantic proximity Read ↗

PKD1 mutant clones within cirrhotic livers inhibit steatohepatitis without promoting cancer.Semantic proximity Read ↗

MASLD-Induced Liver Micro-Organoids Mimics Clinical Observations of Impaired Vitamin D SynthesisSemantic proximity Read ↗

Altered drug metabolism and increased susceptibility to fatty liver disease in myotonic dystrophySemantic proximity Read ↗

Somatic loss-of-function mutations in CIDEB reduce hepatic steatosis by increasing lipolysis and fatty acid oxidationSemantic proximity Read ↗

Ontogeny of drug-induced fatty liver disease (DIFLD): from key initiating events to disease phenotypes.Semantic proximity Read ↗

Interaction of <i>G2019S LRRK2</i> and metabolic syndrome in a two-hit mouse model of Parkinson’s disease: LRRK2-driven systemic depletion of pyrimidine nucleosidesSemantic proximity Read ↗

Inhibiting DPP4 activity protects hiPSC-derived steatotic HLCs by supporting fatty acid and purine metabolism and dampening inflammationSemantic proximity Read ↗

Mechanistic basis for protection against fatty liver disease by <i>CIDEB</i> loss-of-function mutationsSemantic proximity Read ↗

Genome-wide CRISPR screens identified <i>C18orf32</i> as a novel regulator of lipid metabolism that mediates PFOA-induced toxicitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.